Abiomed's explanation of a possible Medicare reimbursement change for its flagship Impella heart pump helps ease its recent share price slide. Shares of Abiomed (NSDQ:ABMD) rebounded nearly 8% today after the medical device company sought to reassure investors about proposed changes to Medicare reimbursement for its flagship Impella heart pump. An analysts' speculation on the effect of proposed new descriptions for Medicare reimbursement codes, slated to take effect in October 2014, sent share prices down nearly 19% last week.
Help employers find you! Check out all the jobs and post your resume.
